DURAGESIC-12
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-12 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers medication through the skin over an extended period, providing sustained therapeutic exposure. Mechanism of action and specific indications are not publicly detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential team restructuring and focus on retention or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DURAGESIC-12 offers limited career growth opportunity due to approaching loss of exclusivity and zero linked job openings. Roles on this product tend to focus on defensive strategies, generic transition planning, and market share protection rather than expansion.
Brand ManagerField Sales Representative
Worked on DURAGESIC-12 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.